行情

KDMN

KDMN

Kadmon控股
NYSE

实时行情|Nasdaq Last Sale

3.920
0.000
0.00%
盘后: 3.940 +0.02 +0.51% 16:36 11/15 EST
开盘
3.970
昨收
3.920
最高
4.110
最低
3.750
成交量
227.55万
成交额
--
52周最高
4.350
52周最低
1.630
市值
5.08亿
市盈率(TTM)
-4.7235
分时
5日
1月
3月
1年
5年

分析师评级

4位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

KDMN 新闻

  • 传John Legere不会成为WeWork的下任CEO
  • 新浪财经综合.17分钟前
  • 日本人引以为傲的24小时营业 正被便利店巨头们放弃
  • 新浪财经综合.28分钟前
  • Fitbit已被谷歌收入囊中 下一个被收购的将是GoPro?
  • 新浪财经综合.38分钟前
  • 美国强生公司因阿片类药物案罚款减少股价上涨约3%
  • 新浪美股.1小时前

更多

所属板块

制药
+1.25%
制药与医学研究
+1.29%

热门股票

名称
价格
涨跌幅

KDMN 简况

Kadmon Holdings, Inc. is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of various unmet medical needs. The Company is developing product candidates in a number of indications within autoimmune and fibrotic disease, oncology and genetic diseases. Its product pipeline consists of KD025, Tesevatinib and KD034. The Company's other products include Ribasphere RibaPak, Ribasphere, Qsymia, Tetrabenazine and Valganciclovir. KD025 is an orally available, selective small molecule inhibitor of Rho-associated coiled-coil kinase 2 (ROCK2), a molecular target in multiple autoimmune, fibrotic and neurodegenerative diseases. Tesevatinib is an oral tyrosine kinase inhibitor (TKI) designed to block key molecular drivers of tumor growth, metastases and drug resistance. KD034 is the Company's portfolio of enhanced formulations of trientine hydrochloride for the treatment of Wilson's disease.
展开

Webull提供Kadmon Holdings Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。